Danis Pharma SA
Danis Pharma reported total assets of 866,100 € at the end of the 2025 financial year (annual accounts filed with the NBB on 29 Jan 2026).
The score of Danis Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +41 % Total assets +12 %
Accounts of the company itself (not consolidated).
The full file covers 15 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Danis Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 71,707 € | ||||
| Equity | 784,088 € | ||||
| Cash | 69,907 € | ||||
| EBITDA | 104,453 € | ||||
| Total assets | 866,100 € |
Filed annual accounts
- Year ended 30 Jun 2025filed on 29 Jan 2026
- Year ended 30 Jun 2024filed on 21 Feb 2025
- Year ended 30 Jun 2023filed on 30 Jan 2024
- Year ended 30 Jun 2022filed on 30 Jan 2023
- Year ended 30 Jun 2021filed on 21 Dec 2021
Danis Pharma's financial analysis
- Solvency90.5%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Danis Pharma
Danis Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0465.345.721
- VAT number
- BE0465345721
- Peppol
- Registered · 0208:0465345721 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 27 Jan 1999
- Registered office
- 1650 Beersel
- Latest accounts
- 2025 · filed on 29 Jan 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Danis Pharma (SA) has been based in Beersel since 1999, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 71,707 € and equity of 784,088 €; its revenue is not published. Its solvency stands at 90.5%, above the median of its sector (44.2%).
Companies similar to Danis Pharma
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie DU Thier-A-Liege Retail sale of pharmaceutical products Liège · balance sheet 865,604 €
- Apotheek Meensepoort Retail sale of pharmaceutical products Kortrijk · balance sheet 866,975 €
- Pharmacies Vissoul Retail sale of pharmaceutical products Thimister-Clermont · balance sheet 867,168 €
- Cosaert & Co Retail sale of pharmaceutical products Knokke-Heist · balance sheet 873,653 €
- A.K. Pharma Retail sale of pharmaceutical products Berchem-Sainte-Agathe · balance sheet 857,382 €
- Pharmazinnes Retail sale of pharmaceutical products Namur · balance sheet 875,224 €
- Lo Farma Retail sale of pharmaceutical products Lochristi · balance sheet 875,320 €
- Bruyaux Pharma Retail sale of pharmaceutical products Mons · balance sheet 856,915 €
Frequently asked questions about Danis Pharma
What is the revenue of Danis Pharma?
Danis Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Danis Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0465345721 for Danis Pharma, if the company is VAT-registered. Its company number (CBE) is 0465.345.721.
Where is the registered office of Danis Pharma?
According to the CBE register, the registered office of Danis Pharma is in 1650 Beersel.
What is the equity of Danis Pharma?
At the close of the 2025 financial year, the equity of Danis Pharma amounts to 784,088 €, a solvency of 90.5% of total assets.
Who manages Danis Pharma?
The register lists 3 active mandates at Danis Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Danis Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →